Telix Pharmaceuticals was created to deliver on the promise of nuclear medicine
The field of nuclear medicine has historically lacked clinical momentum and commitment to late-stage product development. Our goal is to rectify this for the benefit of patients.
Telix Pharmaceuticals Receives $11.4M R&D Tax Refund
Melbourne (Australia) – 21st July 2020. Telix Pharmaceuticals announces it has received an A$11.4M R&D tax refund in relation to...
Telix Pharmaceuticals and RefleXion Medical Enter Strategic Collaboration for Treatment of High-Risk Cancers
Melbourne (Australia) – 8th July 2020. Telix Pharmaceuticals Limited announces it has entered into a strategic collaboration agreement with RefleXion Medical
Telix Granted FDA Breakthrough Therapy Designation for Renal Cancer Imaging Product
Melbourne (Australia) – 1st July 2020. Telix announces that the FDA has granted Breakthrough Therapy (BT) designation for Telix’s renal...
The Seneffe Manufacturing Site – Telix’s Next Big Move in Europe
1st May 2020 - Corporate Spotlight | Telix’s CEO Chris Behrenbruch comments on the Company’s next big move in Europe...